HCPCS Level IItemporaryActive
Q2053
Brexucabtagene car pos t
BETOS: O1E
Effective: 2021-04-01
Referenced in 1 policies
Description
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Medicare Fee Schedule
2026 Medicare Physician Fee Schedule national payment rates
Excluded
This code is excluded from the Medicare Physician Fee Schedule.
Coverage Policies